Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: Safety and tolerability review

Expert Opinion on Drug Safety

Volumn 9, Issue 5, 2010, Pages 683-697

  Cañas, Fernando ^a   Möller, Hans Jürgen ^b  

^a Hospital Dr Rodríguez Lafora   (Spain)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Olanzapine pamoate; Risperidone long acting injectable; Safety and tolerability; Schizophrenia

Indexed keywords

GLUCOSE; HALOPERIDOL; OLANZAPINE; OLANZAPINE PAMOATE; PLACEBO; PROLACTIN; RISPERIDONE; UNCLASSIFIED DRUG;

AGITATION; AKATHISIA; AMENORRHEA; ANXIETY; BREAST DISEASE; CLINICAL TRIAL; DELIRIUM; DELIRIUM SEDATION SYNDROME; DIABETES MELLITUS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSMENORRHEA; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; IMPOTENCE; INFECTION; INFESTATION; INJECTION SITE PAIN; INSOMNIA; LIBIDO DISORDER; MENORRHAGIA; MENSTRUAL IRREGULARITY; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PARKINSONISM; PERIPHERAL EDEMA; PROLACTIN BLOOD LEVEL; PSYCHOSIS; REVIEW; RHINOPHARYNGITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDE; TARDIVE DYSKINESIA; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; HYPERPROLACTINEMIA; INJECTIONS; MEDICATION ADHERENCE; MOVEMENT DISORDERS; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 77955957094     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.506712     Document Type: Review

References (71)

1. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005;6:132-191
2. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006;7:5-40
3. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38
4. Byerly MJ, Thompson A, Carmody T, et al. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv 2007;58:844-847
5. Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 2007;68:818-825
6. Rosa MA, Marcolin MA, Elkis H. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia. Rev Bras Psiquiatr 2005;27:178-184
7. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008;161:235-247
8. Rummel-Kluge C, Schuster T, Peters S, Kissling W. Partial compliance with antipsychotic medication is common in patients with schizophrenia. Aust NZ J Psychiatry 2008;42:82-88
9. Acosta FJ, Bosch E, Sarmiento G, et al. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res 2009;107:213-217
10. Ascher-Svanum H, Zhu B, Faries D, et al. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 2006;67:1114-1123
11. McCann TV, Boardman G, Clark E, Lu S. Risk profiles for non-adherence to antipsychotic medications. J Psychiatr Ment Health Nurs 2008;15:622-629
12. Perkins DO, Gu H, Weiden PJ, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106-113
13. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):3-8
14. Glazer WM, Byerly MJ. Tactics and technologies to manage nonadherence in patients with schizophrenia. Curr Psychiatry Rep 2008;10:359-369
15. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):9-14
16. Patel MX, de Zoysa N, Bernadt M, David AS. A cross-sectional study of patients perspectives on adherence to antipsychotic medication: depot versus oral. J Clin Psychiatry 2008;69:1548-1556
17. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-307
18. Curson DA, Barnes TR, Bamber RW, et al. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. Br J Psychiatry1985;146:469-474
19. Heyscue BE, Levin GM, Merrick JP. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998;49:1232-1234
20. Tunnicliffe S, Harrison G, Standen PJ. Factors affecting compliance with depot injection treatment in the community. Soc Psychiatry Psychiatr Epidemiol 1992;27:230-233
21. Emsley R, Oosthuizen P, Koen L, et al. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 2008;30:2378-2386
22. Kim B, Lee SH, Choi TK, et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1231-1235
23. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-296
24. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64(Suppl 16):14-17
25. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006;67:1948-1953
26. Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007;22:275-282
27. Patel MX, De Zoysa N, Bernadt M, David A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009;23:789-796
28. Martinez G, Schreiner A. Risperidone long-acting injectable and olanzapine pamoate: review of short- and long-term safety data. Presented at the 9th World Federation of Societies of Biological Psychiatry; 29 June - 2 July 2009; Paris, France
29. Moller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 2007;67:1541-1566
30. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132
31. Lindenmayer J, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-1089
32. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-117
33. Moller HJ. Long-acting risperidone: focus on safety. Clin Ther 2006;28:633-651
34. Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004;19:241-249
35. Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomized, controlled, open-label study. Br J Psychiatry 2007;191:131-139
36. Bai YM, Chen TT, Wu B, et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 2006;39:135-141
37. Gastpar M, Masiak M, Latif MA, et al. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol 2005;19(Suppl):32-38
38. Mohl A, Westlye K, Opjordsmoen S, et al. Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol 2005;19(Suppl):22-31
39. Moller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotics. Int Clin Psychopharmacol 2005;20:121-130
40. Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005;19(Suppl):5-14
41. Kissling W, Glue P, Medori R, Simpson S. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol 2007;22:505-513
42. Curtis VA, Katsafouros K, Moller H, et al. Long-acting risperidone improves negative symptoms in stable psychotic patients. J Psychopharmaol 2008;22:254-261
43. Parellada E, Kouniakis F, Siurkute A, et al. Survey of safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, non-interventional prospective study [abstract]. Eur Psychiatry 2009;24(Suppl 1):S1025
44. Rosa F, Schreiner A, Thomas P, Sherif T. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Presented atEuropean Meeting of Psychiatry; 24 - 28 January 2009; Lisbon, Portugal
45. Rabinowitz J, Napryeyenko O, Burba O, et al. Efficacy and tolerability among patients with recent onset schizophrenia treated with long - acting injectable risperidone - PROPEL study. Presented at 9th World Congress of Biological Psychiatry; 28 June - July 2 2009; Paris, France
46. Bai YM, Ting Chen T, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 2007;68:1218-1225
47. Lee MS, Ko YH, Lee SH, et al. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol 2006;21:399-407
48. Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 2005;8:427-438
49. Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone - analysis of long-term efficacy. J Psychopharmacol 2005;19(Suppl 1):15-21
50. Simpson GM, Mahmoud RA, Lasser RA, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006;67:1194-1203
51. Gharabawi GM, Gearhart NC, Lasser RA, et al. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry 2007;6:3
52. Peuskens J, Van der Veken J, Diels J, Povey M. Improvements in illness severity, functioning and hospitalization in schizophrenic patients switched to risperidone long-acting injection (RLAI): 12-month interim report from Belgian patients enrolled in the electronic schizophrenia treatment adherence registry (e-STAR). Poster presented at the American Psychiatric Association Annual Meeting; 19 - 24 May 2007; San Diego, USA
53. Garcia D, Duval F, Lopera FG, et al. Weight gain and hyperprolactinemia in schizophrenic patients treated during twelve months with long acting risperidone [abstract]. Eur Psychiatry 2009;24(Suppl 1):S1004
54. Lindenmayer J, Khan A, Eerdekens M, et al. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007;17:138-144
55. Llorca PM, Sacchetti E, Lloyd K, et al. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Ther 2008;46:14-22
56. Emsley R, Medori R, Koen L, et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008;28:210-213
57. Gaebel W, Bergmans P, de Arce R, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable versus quetiapine: Randomized, long-term, open-label, clinical trial results (ConstaTRE) [abstract]. Eur Psychiatry 2009;24(Suppl 1):S1020
58. Taylor DM, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry 2009;70:196-200
59. Olivares JM, Peuskens J, Pecenak J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-2206
60. Detke HC, McDonnell DP, Lauriello J, et al. Olanzapine long-acting injection: an 8-week double-blind, randomized, placebo-controlled study in acutely-ill patients with schizophrenia [abstract]. Int J Neuropsychopharmacol 2008;11(Suppl 1):152
61. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69:790-799
62. EMEA. European Medicines Agency pre-authorisation evaluation of medicines for human use. Document reference: EMEA/608654/2008. Available from: PDFs/EPAR/Zypadhera/H-890-en6.pdf. [Last accessed 8 March 2010]
63. Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract 2009;63:140-150
64. Eli Lilly and Company. FDA issues not-approvable letter for Lillys Zyprexa® long-acting injection (LAI) for schizophrenia treatment. 2008. Available from: ReleaseDetail.cfm?ReleaseID=296550. [Last accessed 8 March 2010]
65. Gulliver AH, McDonnell DP, Kryzhanovskaya LA, et al. Metabolic parameters during treatment with intramuscular olanzapine. Presented at the Institute on Psychiatric Services; 2 - 5 October 2008; Chicago, IL, USA
66. Detke HC, McDonnell DP, Kane JM, et al. Olanzapine long-acting injection for the maintenance treatment of schizophrenia: a 24-week, randomized, double-blind trial [abstract]. Int J Neuropsychopharmacol 2008;11(Suppl 1):151-152
67. Detke HC, McDonnell DP, Andersen SW, Watson SB. 160-week interim results from an open-label extension trial of olanzapine long-acting injection [abstract]. Int J Neuropsychopharmacol 2008;11(Suppl 1):151
68. Horne RL. Long term open label study of olanzapine pamoate: efficacy and effect on weight. 161st Annual Meeting of the American Psychiatric Association; 3 - 8 May 2008; Arlington, VA, USA
69. De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-424
70. Akhras KS, Singh J, Gopal S, et al. Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres. Int J Clin Pract 2009;63:962-963
71. Sato Y, Yasui-Furukori N, Saito M, et al. Comparison of metabolic factors by cookie test between schizophrenic patients during treatments with olanzapine or risperidone [abstract]. Int J Neuropsychopharmacol 2008;11(Suppl 1):153-154